Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Adenocarcinoma × Pancreaticoduodenectomy × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Pancreatic Neoplasms 29 Pancreatic Fistula 4 Pancreatic Ductal Adenocarcinoma 2 Jaundice, Obstructive 2 Gastroparesis 2 Bile Duct Neoplasms 2 Recurrence 1 Periampullary Cancer 1 Pancreatitis, Chronic 1 Obesity 1 Non-alcoholic Fatty Liver Disease 1 Neoplasm Metastasis 1 Metabolic Syndrome 1 Locally Advanced Pancreatic Adenocarcinoma 1 Hypoxia 1 Hemorrhage 1 Fatty Liver 1 Diabetes Mellitus 1 Cholangiocarcinoma 1 Carcinoma, Pancreatic Ductal 1 Adenocarcinoma 1

Interventions

Oxaliplatin 42 Gemcitabine 41 Fluorouracil 37 pembrolizumab 29 Capecitabine 29 Leucovorin 26 Docetaxel 25 Cisplatin 24 Paclitaxel 21 Carboplatin 18 Bevacizumab 17 Irinotecan 16 130-nm albumin-bound paclitaxel 16 Radiotherapy 15 Pemetrexed 15 Nivolumab 13 Albumin-Bound Paclitaxel 13 Cyclophosphamide 10 Ramucirumab 9 zolbetuximab 7 Trastuzumab 7 Radiosurgery 7 Drug Therapy 7 trastuzumab deruxtecan 6 cemiplimab 6 Taxes 6 Erlotinib Hydrochloride 6 Blood Specimen Collection 6 durvalumab 5 Sorafenib 5

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT01419002 2015-07-29

Net-Pac

CHIR-Net

Phase 3 Terminated

Gastrointestinal

Adenocarcinoma, Pancreatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡